23 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through preclinical studies and clinical trials. Product
ARS
ofkipqnlrg3m1
28 Apr 23
Annual report to shareholders
7:03am
424B4
j1lc dfgv5t
21 Jun 21
Prospectus supplement with pricing info
8:08am
DRS
0ak88nnxk y19l
19 May 21
Draft registration statement
12:00am
10-K
1n9w04tzo3m
11 Mar 21
Annual report
4:19pm
10-Q
fre971nohjv0ukfvwhhl
12 Nov 20
Quarterly report
4:28pm
424B4
ac8v4tp icgwlsniq4n
2 Oct 20
Prospectus supplement with pricing info
5:10pm